UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF
THE SECURITIES EXCHANGE ACT OF 1934
APRINOIA Therapeutics Inc.
(Exact name of registrant as specified in its charter)

Cayman Islands
(State of incorporation or organization)
      
Not Applicable
(I.R.S. Employer Identification No.)

245 Main Street, 2nd Floor
Cambridge, MA 02142
Telephone: 617-225-4415
(Address of principal executive offices)
 
Securities to be registered pursuant to Section 12(b) of the Act:
 
Title of each class
to be so registered
Ordinary shares, par value $0.40 per share
  
Name of exchange on which
each class is to be registered
The Nasdaq Stock Market LLC

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. ☒
 
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. ☐
 
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐
 
Securities Act registration statement file number to which the form relates: 333-276696
 
 
Securities to be registered pursuant to Section 12(g) of the Act: None



INFORMATION REQUIRED IN REGISTRATION STATEMENT
 
Item 1. Description of Registrant’s Securities to be Registered.
 
The description of the securities being registered is set forth under “Description of Share Capital” in the Registrant’s registration statement on Form F-1 (File No. 333-276696), originally filed with the Securities and Exchange Commission on January 26, 2024, as amended, including any form of prospectus contained therein pursuant to Rule 424(b) under the Securities Act of 1933, which description and prospectus are incorporated herein by reference. Copies of such description will be filed with the Nasdaq Stock Market LLC.
 
Item 2. Exhibits.
 
No exhibits are required to be filed as the securities being registered on this form (1) are being registered on an exchange on which no other securities of the Registrant are registered, and (2) are not being registered pursuant to Section 12(g) of the Exchange Act.
 

SIGNATURE
 
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.
 
     
APRINOIA Therapeutics Inc.
     
 
By:
  
/s/ Mark Shearman
 
     
Name:
  
Mark Shearman
     
Title:
  
Chief Executive Officer

 
Dated: September 30, 2024